Market Intelligence, Clinical Progress, and High-Purity Reagents for Ferroptosis, Cancer Metabolism, and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BACH1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BACH1 Recombinant Protein (Full-Length & BTB/bZIP Domains). High purity (>95%), Sequence Verified, Endotoxin <1EU/μg. HEK293 Expressed. | View BACH1 Products |
| Gene Delivery | BACH1 Promise-ORF / Lentivirus Premade Particles. Full-length ORF for stable cell line construction and rescue experiments. | View BACH1 Products |
| Benchmark Ab | Anti-BACH1 Monoclonal Antibody (ChIP/IF/WB Grade). Recombinant positive control for target engagement and occupancy studies. | View BACH1 Products |
| Validator | BACH1 siRNA Set (3 unique sequences). For knockdown verification; guaranteed >70% mRNA reduction. | View BACH1 Products |
| Heterodimer Partner | MAFF Recombinant Protein. Small Maf protein partner for BACH1 dimerization assays. High purity. | View MAFF Products |
| Pathway Comparator | NFE2L2 (NRF2) Recombinant Protein. CNC-bZIP homolog for selectivity counter-screening. | View NFE2L2 Products |
| Upstream Regulator | KEAP1 Recombinant Protein. Regulatory partner for comprehensive antioxidant pathway studies. | View KEAP1 Products |
| Related Target | HMOX1 Recombinant Protein. Direct downstream effector, key for ferroptosis pathway validation. | View HMOX1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PROTAC Ternary Complex Validation | Sequence Verified, High Purity (>95%) domain-specific recombinant proteins (BTB domain) without aggregation. |
| Heme-binding conformation integrity for competition assays | BACH1 CNC domain protein expressed in HEK293 with theoretical heme-binding capability; verified cysteine residue positioning. |
| Selectivity vs. homologous CNC-bZIP family (NRF2, NFE2, BACH2) | Ortholog protein panel (NFE2L2, BACH2, NFE2) available with >95% purity for cross-reactivity screening. |
| BACH1-Maf heterodimer disruption screening | Co-available MAFF/MAFG/MAFK proteins for AlphaScreen/FP assay; endotoxin-free. |
| Transcription factor DNA-binding fidelity (bZIP domain) | Full-length & bZIP-domain BACH1 proteins for EMSA / AlphaScreen. |
| Nuclear transcription factor cell-based validation | Lentivirus ORF particles for stable BACH1-overexpression lines; suitable for reporter gene and degradation assays. |
| False positive elimination in binding assays | Validated siRNA included for target-specificity verification in cellular contexts. |
Live BACH1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BACH1-targeted therapeutics is intensifying as a strategic approach to induce ferroptosis in resistant tumors and overcome immune evasion. BACH1, an intracellular CNC-bZIP transcription factor (UniProt O14867) with BTB and bZIP domains, has historically been considered "undruggable" due to lack of deep active sites. However, recent advances in targeted protein degradation (PROTACs) and heme-competitive small molecules are unlocking its therapeutic potential. Major players are shifting from traditional small molecule inhibitors to PROTAC degraders, with emerging focus on combination regimens that pair BACH1 blockade with GPX4 inhibitors, KEAP1 activators, or immune checkpoint inhibitors to maximize immunogenic cell death and overcome tumor adaptivity. Key indications include triple-negative breast cancer (TNBC), lung adenocarcinoma, pancreatic cancer, and metastatic solid tumors. The clinical landscape remains preclinical to early clinical, with accelerating momentum in academia and biotech.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic consortia, Emerging biotechs (Heme analogs) | TNBC, Lung Cancer, Pancreatic Cancer | Heme Competition Binding Assay (Need pure BACH1 CNC domain) |
| PROTAC Degraders | Arvinas, Academic spin-offs, Targeted degradation platforms | TNBC, Lung Cancer, Solid Tumors | Cellular Degradation Assay & Ternary Complex Assay (Need high-purity BTB/protein, Lentivirus reporters) |
| RNAi / ASO | Alnylam, Ionis (Exploratory) | Neurodegeneration, NASH | Cellular Knockdown (Need reliable Lentivirus for models) |
| Ferroptosis Inducer Combination | Immuno-oncology research groups | Drug-Resistant Tumors, Refractory Cancers | Ferroptosis Induction Assay (Need BACH1+MAFF heterodimer proteins) |
| Combination Immunotherapy | I-O research groups | Refractory Cancers | Pathway selectivity panel (Need KEAP1/NRF2/BACH2 proteins) |
Note: The key mutation rs35474725 (dbSNP) is documented in UniProt (VAR_048441) and may be relevant for resistance studies.